Immunome, Inc. (IMNM) Balance Sheet
As of 2026-06-30 (10-Q), Immunome, Inc. (IMNM) reported total assets of $565.4M, total liabilities of $40.3M and shareholders' equity of $525.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $217.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMNMImmunome, Inc.Follow IMNM — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 39.8 | 49.2 | 20.3 | 98.7 | 143.4 | 653.5 | 217.7 | |
| Short-term investments | — | — | — | 39.5 | 74.0 | 0.0 | 302.3 | |
| Current assets | 42.9 | 56.6 | 22.6 | 144.7 | 221.3 | 660.8 | 538.4 | |
| Total assets | 44.5 | 57.9 | 24.0 | 148.5 | 240.2 | 683.2 | 565.4 | |
| Current liabilities | 3.0 | 9.7 | 7.3 | 21.8 | 54.3 | 45.0 | 35.7 | |
| Long-term debt | 0.1 | — | — | — | — | — | — | |
| Short-term debt | 0.4 | — | — | — | — | — | — | |
| Total liabilities | 3.2 | 9.7 | 7.4 | 28.7 | 59.1 | 48.8 | 40.3 | |
| Shareholders' equity | 41.3 | 48.2 | 16.7 | 119.9 | 181.2 | 634.3 | 525.1 |
USD millions · SEC XBRL
Immunome, Inc. — questions
- How much cash does Immunome, Inc. have?
- $217.7M in cash and cash equivalents as of 2026-06-30.
- What are Immunome, Inc.'s total assets?
- $565.4M as of 2026-06-30.
- What is Immunome, Inc.'s shareholders' equity?
- $525.1M as of 2026-06-30.
Every figure on this page comes from Immunome, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.